Portea posts Rs 160 Cr revenue in FY25; narrows losses

Portea, a Bengaluru-based home healthcare services provider, has halved its losses during the fiscal year ended March 2025. The improvement came on the back of steady revenue growth with controlled expenses in the period.

Portea’s revenue from operations grew by 15% to Rs 160 crore in FY25 from Rs 139 crore in FY24, according to its consolidated financial statements sourced from the Registrar of Companies (RoC).

Portea offers a range of at-home healthcare services such as nursing, physiotherapy, medical equipment rentals, attendant care, lab tests, consultations, and specialised care.

Revenue from these services remained the largest contributor, accounting for 59% of operating income, which rose by 16% year-on-year to Rs 95 crore in FY25. Meanwhile, revenue from product sales, including oxygen concentrators, BiPAP machines, and nebulisers, grew 14% to Rs 56 crore in FY25.

Looking at the expenses, the employee benefit cost declined by 4.5% to Rs 52.5 crore in FY25. Its consultancy expenses rose 7% to Rs 44 crore. Meanwhile, the cost of materials increased 21% to Rs 52 crore, and advertisement expenses rose 25% to Rs 7.5 crore during the fiscal year.

Other overheads, including legal and professional charges, and finance costs, added over Rs 30 crore to the total expense. Overall, Portea kept its total expenses flat at Rs 179 crore in FY25.

With revenue rising and costs remaining stable, Portea managed to cut its loss by 49% to Rs 19 crore in FY25 from Rs 37 crore in FY24. Its ROCE and EBITDA margins stood at -40.54% and -6.88%, respectively. 

On a unit basis, Portea spent Rs 1.12 to earn a rupee during the fiscal year, improving from Rs 1.29 in FY24. The company reported cash and bank balances of Rs 1 crore, while its current assets stood at Rs 68 crore as of March 2025.

According to TheKredible, Portea has raised nearly $123 million in funding to date, having Accel and Ventureast as its lead investors.

It is worth noting that Portea received SEBI’s approval in 2023 to launch a Rs 1,000 crore initial public offering, but the company has since not taken any further steps to move ahead with the listing.